Macitentan in Pulmonary Hypertension of Sickle Cell Disease
Status:
Terminated
Trial end date:
2019-12-18
Target enrollment:
Participant gender:
Summary
This is a pilot study to assess the safety and efficacy of macitentan in patients with
pulmonary hypertension of sickle cell disease. This study will enroll approximately 10
subjects. Study participation for each subject will last approximately 24 weeks from
screening to end of treatment follow-up.